Relief For Cancer Patients Suffering From Opioid-Induced Bowel Disorders

Methylnaltrexone, a drug developed to relieve one of the major side effects of pain therapy for cancer patients, received marketing approval from the United States Food and Drug Administration on April 24, 2008, for use in the treatment of opioid-induced bowel disorders in patients receiving palliative care for advanced illness such as cancer.

More: continued here

Filed under: Pain / Anesthetics on May 15th, 2008